

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Joseph M. Penninger et al.

Serial No.: 10/518,599

Filed: December 17, 2004

For: ACE2 ACTIVATION FOR TREATMENT  
OF HEART, LUNG AND KIDNEY  
DISEASE AND HYPERTENSION

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: SONN:064US

## EXPRESS MAIL MAILING LABEL

NUMBER EV 414867445 US

DATE OF DEPOSIT May 31, 2005

INFORMATION DISCLOSURE STATEMENT

MS PCT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/SONN:064US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Mark B. Wilson  
Reg. No. 37,259  
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: May 31, 2005

#7

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

SONN:064US

10/518,599

**List of Patents and Publications for Applicant's****Applicant**

Joseph M. Penninger et al.

**INFORMATION DISCLOSURE STATEMENT****Filing Date:**

December 17, 2004

**Group:**

Unknown

**U.S. Patent Documents***See Page 1***Foreign Patent Documents***See Page 1***Other Art***See Page 1***U.S. Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

**Foreign Patent Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 02/12471	2/14/02	WIPO			

**Other Art (Including Author, Title, Date Pertinent Pages, Etc.)**

Exam. Init.	Ref. Des.	Citation
	C1	Crackower et al., "Angiotensin-converting enzyme 2 is an essential regulator of heart function," <i>Nature</i> , 417:822-828, 2002.
	C2	Donoghue et al., "A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9," <i>Circulation Research</i> , 87:e1-e9, 2000.
	C3	Gramatikoff "Angiotensin-converting enzyme 2 regulates heart function," Database Biocarta, 2002.
	C4	Yagil et al., "Role of chromosome X in the sagra rat model of salt-sensitive hypertension," <i>Hypertension</i> , 33:261-265, 1999.

25539573.1

EXAMINER: /Tekchand Saidha/ (04/21/2010) DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.S./